News
CRVO: $150 Million Financing Strengthens Balance Sheet; Topline Data for Phase 2b Trial in 4Q24
15 Apr 24
News, Health Care, Markets, Trading Ideas, General
Disney To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Monday
8 Apr 24
News, Price Target, Small Cap, Pre-Market Outlook, Markets, Analyst Ratings, Trading Ideas
Canaccord Genuity Maintains Buy on CervoMed, Raises Price Target to $65
8 Apr 24
News, Price Target, Analyst Ratings
12 Health Care Stocks Moving In Thursday's Intraday Session
21 Mar 24
Movers
CervoMed Announces Presentation Of Biomarker Data From The AscenD-LB Phase 2a Trial And Preclinical Data Supporting Potential Of Neflamapimod In Tau-Mediated Disease At AD/PD 2024
5 Mar 24
Biotech, News, General
Canaccord Genuity Initiates Coverage On CervoMed with Buy Rating, Announces Price Target of $50
15 Feb 24
News, Price Target, Initiation, Analyst Ratings
CervoMed Publishes Results From AscenD-LB Phase 2a Trial Evaluating Treatment Of Neflamapimod In Dementia With Lewy Bodies
12 Feb 24
Biotech, News, General
CervoMed Appoints Joshua Boger As Board Chair
7 Feb 24
News, Management
Press releases
Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
2 Apr 24
Press Releases
CervoMed to Participate in the BIO CEO and Investor Conference
21 Feb 24
News, Press Releases
CervoMed appoints drug development veteran Dr. Joshua Boger as Chairman of the Board
20 Feb 24
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
12 Feb 24
Press Releases
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
7 Feb 24
News, Management, Press Releases
CervoMed to Participate in the Emerging Growth Conference 67
5 Feb 24
News, Press Releases